Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: A preliminary report

E. Hodak, Gil Yosipovitch, M. David, A. Ingber, L. Chorev, O. Lider, L. Cahalon, I. R. Cohen

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Background: Low-dose heparin devoid of anticoagulant activity inhibits T-lymphocyte heparanase activity, which is crucial in T-cell migration to target tissues. Objective: The purpose of this study was to assess the efficacy of low-dose enoxaparin (Clexane), a low-molecular-weight heparin, as monotherapy in lichen planus. Methods: Included in the study were 10 patients with widespread histopathologically proven lichen planus (LP) associated with intense pruritus of several months' duration. Patients were given 3 mg enoxaparin, subcutaneously once weekly; three patients received four injections, and seven patients received six injections. Results: In nine patients the itch disappeared within 2 weeks. Within 4 to 10 weeks in eight of these patients, there was complete regression of the eruption with residual postinflammatory hyperpigmentation; in one patient, there was marked improvement. In one patient, no effect was observed. Of the four patients who also had oral LP, only one showed improvement. No side effects were observed in any of the patients. Conclusion: These findings indicate that enoxaparin may be a simple, effective treatment for cutaneous LP.

Original languageEnglish (US)
Pages (from-to)564-568
Number of pages5
JournalJournal of the American Academy of Dermatology
Volume38
Issue number4
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

Enoxaparin
Lichen Planus
Low Molecular Weight Heparin
Oral Lichen Planus
T-Lymphocytes
Hyperpigmentation
Injections
Pruritus
Anticoagulants
Cell Movement
Heparin

ASJC Scopus subject areas

  • Dermatology

Cite this

Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus : A preliminary report. / Hodak, E.; Yosipovitch, Gil; David, M.; Ingber, A.; Chorev, L.; Lider, O.; Cahalon, L.; Cohen, I. R.

In: Journal of the American Academy of Dermatology, Vol. 38, No. 4, 01.01.1998, p. 564-568.

Research output: Contribution to journalArticle

Hodak, E. ; Yosipovitch, Gil ; David, M. ; Ingber, A. ; Chorev, L. ; Lider, O. ; Cahalon, L. ; Cohen, I. R. / Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus : A preliminary report. In: Journal of the American Academy of Dermatology. 1998 ; Vol. 38, No. 4. pp. 564-568.
@article{1a1cd16ca0714e148ef982bbe0695726,
title = "Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: A preliminary report",
abstract = "Background: Low-dose heparin devoid of anticoagulant activity inhibits T-lymphocyte heparanase activity, which is crucial in T-cell migration to target tissues. Objective: The purpose of this study was to assess the efficacy of low-dose enoxaparin (Clexane), a low-molecular-weight heparin, as monotherapy in lichen planus. Methods: Included in the study were 10 patients with widespread histopathologically proven lichen planus (LP) associated with intense pruritus of several months' duration. Patients were given 3 mg enoxaparin, subcutaneously once weekly; three patients received four injections, and seven patients received six injections. Results: In nine patients the itch disappeared within 2 weeks. Within 4 to 10 weeks in eight of these patients, there was complete regression of the eruption with residual postinflammatory hyperpigmentation; in one patient, there was marked improvement. In one patient, no effect was observed. Of the four patients who also had oral LP, only one showed improvement. No side effects were observed in any of the patients. Conclusion: These findings indicate that enoxaparin may be a simple, effective treatment for cutaneous LP.",
author = "E. Hodak and Gil Yosipovitch and M. David and A. Ingber and L. Chorev and O. Lider and L. Cahalon and Cohen, {I. R.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S0190-9622(98)70118-5",
language = "English (US)",
volume = "38",
pages = "564--568",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus

T2 - A preliminary report

AU - Hodak, E.

AU - Yosipovitch, Gil

AU - David, M.

AU - Ingber, A.

AU - Chorev, L.

AU - Lider, O.

AU - Cahalon, L.

AU - Cohen, I. R.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Background: Low-dose heparin devoid of anticoagulant activity inhibits T-lymphocyte heparanase activity, which is crucial in T-cell migration to target tissues. Objective: The purpose of this study was to assess the efficacy of low-dose enoxaparin (Clexane), a low-molecular-weight heparin, as monotherapy in lichen planus. Methods: Included in the study were 10 patients with widespread histopathologically proven lichen planus (LP) associated with intense pruritus of several months' duration. Patients were given 3 mg enoxaparin, subcutaneously once weekly; three patients received four injections, and seven patients received six injections. Results: In nine patients the itch disappeared within 2 weeks. Within 4 to 10 weeks in eight of these patients, there was complete regression of the eruption with residual postinflammatory hyperpigmentation; in one patient, there was marked improvement. In one patient, no effect was observed. Of the four patients who also had oral LP, only one showed improvement. No side effects were observed in any of the patients. Conclusion: These findings indicate that enoxaparin may be a simple, effective treatment for cutaneous LP.

AB - Background: Low-dose heparin devoid of anticoagulant activity inhibits T-lymphocyte heparanase activity, which is crucial in T-cell migration to target tissues. Objective: The purpose of this study was to assess the efficacy of low-dose enoxaparin (Clexane), a low-molecular-weight heparin, as monotherapy in lichen planus. Methods: Included in the study were 10 patients with widespread histopathologically proven lichen planus (LP) associated with intense pruritus of several months' duration. Patients were given 3 mg enoxaparin, subcutaneously once weekly; three patients received four injections, and seven patients received six injections. Results: In nine patients the itch disappeared within 2 weeks. Within 4 to 10 weeks in eight of these patients, there was complete regression of the eruption with residual postinflammatory hyperpigmentation; in one patient, there was marked improvement. In one patient, no effect was observed. Of the four patients who also had oral LP, only one showed improvement. No side effects were observed in any of the patients. Conclusion: These findings indicate that enoxaparin may be a simple, effective treatment for cutaneous LP.

UR - http://www.scopus.com/inward/record.url?scp=0031897574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031897574&partnerID=8YFLogxK

U2 - 10.1016/S0190-9622(98)70118-5

DO - 10.1016/S0190-9622(98)70118-5

M3 - Article

C2 - 9555795

AN - SCOPUS:0031897574

VL - 38

SP - 564

EP - 568

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 4

ER -